| ID | 10137 |
| Vaccine Name | ProQuad |
| Disease Name | Measles, Mumps, Rubella, Varicella |
| Disease Classification | Exanthous |
| Virus Name | Morbillivirus, Mumps virus, Rubella virus, Varicella-zoster virus |
| Nucleic Acid Content | negative-sense, single-stranded RNA |
| Vaccine Type | Live-attenuated |
| Vaccine Status | Approved |
| Manufacturer | Merck & Co. Inc. |
| Year of Manufacturing | NA |
| Manufacturing Country | USA |
| Age | 1 - 12 years |
| Dosage | First dose at 12 through 15 months of age and Second dose at 4 through 6 years of age |
| Administration Route | Subcutaneous |
| Adjuvant | NA |
| Target Strain | NA |
| Description | NA |
| Approving Organisation | US FDA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NCT00985166 |
| Reference Link | https://www.cdc.gov/vaccines/vpd/varicella/index.html |
| Additional Links | https://www.fda.gov/vaccines-blood-biologics/vaccines/proquad
|